Bapineuzumab

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022

Retrieved on: 
Sunday, July 31, 2022
AAIC, PBD, Brain, Government budget balance, Euronext Amsterdam, Toxicity, Bapineuzumab, CCL2, Learning, Hoffmann, Breakfast, Ageing, Murinae, Biomarker, Safety, Hospital, Moa, Conference, MMSE, Inflammation, PDT, AD, Amyloid-related imaging abnormalities, Company, Neurotoxicity, Aggregation, QPCT, Patient, Memory, Combination, APP, CDC, Harvard Medical School, Hippocampus, Animal, CEST, Medical imaging, Pharmaceutical industry, Vaccine, Amyloid beta

The results underscore the unique potential of Vivoryons N3pE amyloid-targeting therapeutic strategy in both mono- and combination therapy settings in Alzheimers disease (AD).

Key Points: 
  • The results underscore the unique potential of Vivoryons N3pE amyloid-targeting therapeutic strategy in both mono- and combination therapy settings in Alzheimers disease (AD).
  • Secondly, in an effort to overcome the limitations of existing anti-Abeta antibody-based approaches, Vivoryon is developing the monoclonal antibody PBD-C06.
  • Toxic N3pE amyloid correlates with cognitive (MMSE) status in patients suffering from AD and is not found in healthy individuals.
  • The animals were treated with either varoglutamstat, chimeric aducanumab (chAdu) or a combination of both for 16 weeks.

Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis

Retrieved on: 
Wednesday, June 23, 2021
Research, Mental health, Genetics, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Branches of biology, Amyloidosis, Biology, Alzheimer's disease, Neuroscience, Monoclonal antibodies, Anticonvulsants, Homotaurine, Amyloid, Alzheon, Bapineuzumab, ALZ-801, Alzheon, ALZ-801, ALZHEON

This positions ALZ-801 to potentially become the first oral disease-modifying agent for patients and healthy people at high risk for Alzheimers disease.

Key Points: 
  • This positions ALZ-801 to potentially become the first oral disease-modifying agent for patients and healthy people at high risk for Alzheimers disease.
  • The publication provides an up-to-date summary of longitudinal clinical data elucidating the chronology of amyloid and tau biomarkers in AD, and review of non-clinical studies and clinical trials supporting the upstream pathogenic role of amyloid oligomers in AD.
  • Analyze data on clearance of amyloid plaques in amyloid antibody trials showing that even complete plaque removal does not correlate with clinical efficacy.
  • ALZ-801is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain.

Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury

Retrieved on: 
Tuesday, April 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Treatment of Alzheimer's disease, Clinical trials, Monoclonal antibodies, Palifermin, Bapineuzumab

Based on preclinical and human data, as well as promising safety results from our study of PNT001 in healthy volunteers, we believe our investigational therapy has the potential to block the spread of neurotoxic tau observed in traumatic brain injury.

Key Points: 
  • Based on preclinical and human data, as well as promising safety results from our study of PNT001 in healthy volunteers, we believe our investigational therapy has the potential to block the spread of neurotoxic tau observed in traumatic brain injury.
  • The randomized, double-blind, placebo-controlled multiple ascending dose study will enroll 64 patients across two dose level cohorts that, based on the Phase 1 study in healthy volunteers, will provide potentially therapeutic cerebrospinal fluid concentrations of PNT001.
  • Patients will be randomized to receive three monthly intravenous doses of PNT001 or placebo, and will receive their first dose within 24 hours of documented traumatic brain injury.
  • Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Wednesday, October 28, 2020
Branches of biology, Health sciences, Health, Neuroimaging, Clinical research, Design of experiments, Abnormal psychology, Alzheimer's disease, Amyloid-related imaging abnormalities, Clinical trial, Bapineuzumab, Alzheimer's Disease Neuroimaging Initiative

The first oral presentation will cover clinical study design and initial screening results of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients.

Key Points: 
  • The first oral presentation will cover clinical study design and initial screening results of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients.
  • The second oral presentation will cover the latest analysis results on expression of amyloid-related imaging abnormalities-edema (ARIA-E) from the Phase II study (Study 201) conducted on early AD patients.
  • The fourth oral presentation will cover baseline characteristics of currently enrolled subjects in the Phase III study Clarity AD being conducted on early AD patients.
  • Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.